title: Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease.
abstract: METHODS
  The number of patients with chronic kidney disease (CKD) are increasing. Interventions such as controlling hypertension and specific pharmacologic options are recommended. Some nutraceutics may have benefits in this regard.
  
  
  RESULTS
  Naringenin (a flavanon), catechin (a flavanol), and quercetin (a flavonol) and rutin (a flavonol rutinoside) were tried on CKD in a Sprague Dawley rat model. Results indicated quercetin to be the most effective therapeutic candidate with respect to renal edema, hypertension, serum creatinine, hematocrit, cardiopathy, aorta calcification, glomerular amyloidosis, erythrocyte depletion in bone marrow, collagen deposition, expressions of TNF-α, cleaved caspase-3, IκBα, PPARα, and serum insulin. But quercetin was only partially effective in restoring glomerular filtration rate, albuminuria, serum cholesterol, triglyceride, blood urea nitrogen (BUN), uric acid, malondialdehyde, superoxide dismutase; urinary BUN and urinary creatinine. As for signaling, quercetin was completely effective in alleviating the cleaved caspase-3, being only partially effective in suppressing Bax and Bad, restoring Bcl-2, and rescuing DNA damage.
  
  
  CONCLUSIONS
  The CKD status cannot to be ameliorated by naringenin, rutin, and catechin. Comparatively, quercetin may be a better therapeutic candidate.
authors.affiliation: Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
authors.forename: Chiung-Chi
authors.initials: CC
authors.lastname: Peng
authors.forename: Chiu-Lan
authors.initials: CL
authors.lastname: Hsieh
authors.forename: Yaw-Bee
authors.initials: YB
authors.lastname: Ker
authors.forename: Hsi-Yi
authors.initials: HY
authors.lastname: Wang
authors.forename: Kuan-Chou
authors.initials: KC
authors.lastname: Chen
authors.forename: Robert Y
authors.initials: RY
authors.lastname: Peng
mesh_terms: D000419:Albuminuria / Q000188:drug therapy / Q000503:physiopathology; D000818:Animals; D001806:Blood Urea Nitrogen; D053148:Caspase 3 / Q000235:genetics / Q000378:metabolism; D002392:Catechin / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood / Q000652:urine; D019587:Dietary Supplements; D004317:Doxorubicin / Q000633:toxicity*; D044950:Flavanones / Q000008:administration & dosage; D005919:Glomerular Filtration Rate / Q000187:drug effects; D020287:In Situ Nick-End Labeling; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects; D047493:PPAR alpha / Q000235:genetics / Q000378:metabolism; D011794:Quercetin / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D051436:Renal Insufficiency, Chronic / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D012431:Rutin / Q000008:administration & dosage; D013482:Superoxide Dismutase / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism; D051025:bcl-Associated Death Protein / Q000235:genetics / Q000378:metabolism
chemical_list: C494821:Bad protein, rat; C494828:Bax protein, rat; D044950:Flavanones; D007328:Insulin; D047493:PPAR alpha; D014280:Triglycerides; D051028:bcl-2-Associated X Protein; D051025:bcl-Associated Death Protein; D014527:Uric Acid; D008315:Malondialdehyde; D012431:Rutin; D004317:Doxorubicin; D002392:Catechin; D002784:Cholesterol; D011794:Quercetin; D003404:Creatinine; D013482:Superoxide Dismutase; C505410:Casp3 protein, rat; D053148:Caspase 3; C005273:naringenin